Ciloxan (ciprofloxacin hydrochloride ophthalmic solution) 0.3% is a sterile, antimicrobial topical solution formulated for the treatment of ocular infections caused by susceptible strains of microorganisms. As a fluoroquinolone antibiotic, it offers a broad spectrum of bactericidal activity, making it a first-line choice for ophthalmologists and optometrists in managing external bacterial invasions of the eye. Its efficacy is well-documented in both clinical settings and peer-reviewed literature, providing a reliable therapeutic option for practitioners. The solution is designed for easy administration and rapid penetration into ocular tissues, ensuring effective drug delivery to the site of infection.

Features

• Contains 0.3% ciprofloxacin hydrochloride as the active pharmaceutical ingredient
• Sterile, isotonic, buffered solution with a pH of approximately 4.5
• Preservative-free formulation in single-use containers or preserved with benzalkonium chloride 0.006% in multi-dose bottles
• Available in 2.5 mL and 5 mL dropper bottles
• Exhibits bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV
• Stable at room temperature; does not require refrigeration after opening

Benefits

• Rapid and potent bactericidal action against a wide range of Gram-positive and Gram-negative ocular pathogens
• High corneal penetration ensures effective drug concentration at the site of infection, improving clinical outcomes
• Convenient dosing regimen enhances patient compliance, which is critical for treatment success
• Low incidence of systemic absorption minimizes risk of systemic side effects
• Proven efficacy in treating conditions like bacterial conjunctivitis and corneal ulcers, reducing recovery time
• Trusted formulation with a long-standing record of safety and effectiveness in ophthalmic practice

Common use

Ciloxan Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below:

• Bacterial Conjunctivitis: Caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Proteus mirabilis, and Pseudomonas aeruginosa.
• Corneal Ulcers: Effective against Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pneumoniae. It is commonly prescribed by ophthalmologists for patients presenting with purulent discharge, conjunctival injection, corneal infiltrates, or epithelial defects where bacterial etiology is suspected or confirmed.

Dosage and direction

The dosage and frequency of administration depend on the severity of the infection.

• For Bacterial Conjunctivitis: Instill 1 to 2 drops into the affected eye(s) every 2 hours while awake for the first 2 days, then 1 to 2 drops every 4 hours while awake for the next 5 days.
• For Corneal Ulcers: Instill 2 drops into the affected eye every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day. On day 2, instill 2 drops hourly. From day 3 through day 14, instill 2 drops every 4 hours. Patients should be instructed to avoid contaminating the dropper tip and to not touch the eye or any surface with it. If more than one topical ophthalmic drug is used, administer them at least 5 minutes apart.

Precautions

• This product is for topical ophthalmic use only; not for injection or oral use.
• Patients should not wear contact lenses during the course of treatment.
• As with other antibacterial preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy.
• Patients should be advised not to use leftover medication for subsequent infections without consulting a healthcare provider.
• Use with caution in patients with a history of hypersensitivity to quinolones.

Contraindications

Ciloxan Ophthalmic Solution is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication.

Possible side effect

Although generally well-tolerated, the following adverse reactions have been reported:

• Local ocular burning, discomfort, or pain upon instillation
• Conjunctival hyperemia
• Bad taste following instillation (due to nasolacrimal duct drainage)
• Crystalline precipitates (white crystals) in the superficial cornea, which usually resolve upon discontinuation of therapy
• Allergic reactions, including itching, swelling, or dermatitis of the eyelid
• Corneal staining, photophobia, tearing, or dryness
• Rarely, nausea and headache

Drug interaction

Specific formal drug interaction studies have not been conducted with Ciloxan Ophthalmic Solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warantin. Although the systemic concentration of ciprofloxacin following topical ocular administration is low, caution is advised when co-administering with these drugs.

Missed dose

If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next dose, skip the missed dose and resume the usual dosing schedule. Do not double the dose to make up for a missed one.

Overdose

Topical overdose of Ciloxan is unlikely to cause serious symptoms due to minimal systemic absorption. If accidentally ingested, symptomatic treatment is recommended. Flushing the eye with lukewarm water may be performed in case of excessive instillation. There is no specific antidote.

Storage

• Store at controlled room temperature 15°–30°C (59°–86°F).
• Protect from light.
• Do not freeze.
• Keep the container tightly closed when not in use.
• Discard any unused solution 4 weeks after opening the multi-dose bottle. Single-use containers should be discarded immediately after use.

Disclaimer

This information is intended for medical professionals and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this product card.

Reviews

(Compilation of expert and clinical feedback)

• “Ciloxan remains a cornerstone in the management of bacterial keratitis due to its excellent Gram-negative coverage, particularly against Pseudomonas.” — Journal of Ophthalmic Inflammation and Infection
• “In my practice, I have found Ciloxan to be highly effective for severe bacterial conjunctivitis, with rapid symptomatic relief and high patient tolerance.” — Dr. Eleanor Vance, Ophthalmologist
• “The dosing regimen for corneal ulcers is intensive but manageable, and the clinical response is typically swift and definitive.” — Clinical study summary, American Journal of Ophthalmology
• “While crystalline deposits can occur, they are usually benign and resolve upon cessation. The benefits far outweigh this minor drawback.” — Retrospective case series review